Moderna (MRNA)

Executive Summary

Moderna, a pioneer in mRNA technology, has established itself as a key player in the vaccine space with its COVID-19 vaccine, Spikevax. The company is now leveraging its platform to build a diversified pipeline targeting infectious diseases, oncology, rare diseases, and autoimmune disorders. With a strong balance sheet and manufacturing capabilities, Moderna is focused on developing next-generation vaccines, including a seasonal combination vaccine for respiratory viruses and a vaccine for respiratory syncytial virus (RSV). The company's near-term growth hinges on the clinical and regulatory progress of its RSV vaccine (mRNA-1345) and its multivalent respiratory vaccine (mRNA-1010). Positive data from the ongoing Phase 3 RSV trial could unlock a large market opportunity, while early-stage combo vaccine data may support a broader vaccine franchise. However, Moderna faces risks from declining COVID vaccine demand and intense competition in RSV. Overall, the pipeline, while promising, remains unproven in non-COVID indications, warranting a cautious outlook.

Upcoming Catalysts (preview)

• Q3 2026RSV Vaccine (mRNA-1345) Phase 3 Data Readout60% success
• H2 2026Influenza/RSV Combination Vaccine (mRNA-1010) Phase 1 Data40% success
• H1 2027RSV Vaccine Regulatory Filing (if positive data)70% success